Evidence map›Paper›PMID 28607007›Full record

ArticleMolecular cancer research : MCR2017

Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Ahmed A Mohamed, Shyh-Han Tan, Charles P Xavier, Shilpa Katta, Wei Huang, Lakshmi Ravindranath, Muhammad Jamal, Hua Li, Meera Srivastava, Eri S Srivatsan and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Prostate Cancer Stem Cells: Biology and Treatment Implications.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Targeting treatment options for castration-resistant prostate cancer.American journal of clinical and experimental urology · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Ahmed A MohamedCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Shyh-Han TanCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Charles P XavierCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Shilpa KattaCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Wei HuangCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Lakshmi RavindranathCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Muhammad JamalCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Hua LiCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Meera SrivastavaDepartment of Anatomy, Physiology and Genetics, Uniformed University of Health Sciences, Bethesda, Maryland.
Eri S SrivatsanDivision of General Surgery, Department of Surgery, VAGLAHS/David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California.
Taduru L SreenathCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
David G McLeodCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Alagarsamy SrinivasanCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Gyorgy PetrovicsCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland.
Albert DobiCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland. ssrivastava@cpdr.org adobi@cpdr.org.
Shiv SrivastavaCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland. ssrivastava@cpdr.org adobi@cpdr.org.
Walter Reed National Military Medical Center · USUniformed Services University of the Health Sciences · USUniversity of California, Los Angeles · US

Funding

Cell Specific Expression Signatures in Prostate Cancer (RO1 DK065977)R01CA162383 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2011 to 2015
$1.1M
Cell Specific Expression Signatures in Prostate CancerR01DK065977 · NIDDK · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2004 to 2007
$688k
NCI NIH HHS R01 CA162383NIDDK NIH HHS R01 DK065977
6 · The paper itself

Abstract

The oncogenic activation of the ETS-related gene (

Indexed as

Androgen AntagonistsAndrostenesAnilidesBenzamidesCell Line, TumorCell ProliferationCell SurvivalDrug SynergismHumansMaleNitrilesOligopeptidesPhenylthiohydantoinProstatic NeoplasmsReceptor, Notch1Receptor, Notch2abirateroneAndrogen AntagonistsAndrostenesAnilidesBenzamidesbenzyloxycarbonyl-leucyl-leucyl-norleucinalbicalutamideenzalutamideERG protein, humanNitrilesNOTCH1 protein, humanOligopeptidesPhenylthiohydantoinReceptor, Notch1Receptor, Notch2Receptors, NotchTosyl CompoundsTranscriptional Regulator ERG

Identifiers

PMID28607007
PMCPMC5626592
OpenAlexW2626317664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.